Log In
Print
BCIQ
Print
Print this Print this
 

SYN-005

  Manage Alerts
Collapse Summary General Information
Company Synthetic Biologics Inc.
DescriptionHuman mAb against Bordetella pertussis
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationPertussis
Indication DetailsTreat pertussis
Regulatory Designation

U.S. - Orphan Drug (Treat pertussis)

Partner

Intrexon Corp.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today